Patient Outcomes Reporting for Timely Assessments of Life With Depression: PORTAL-Depression

NACompletedINTERVENTIONAL
Enrollment

4,161

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
DepressionDepressive Disorder, Major
Interventions
DIAGNOSTIC_TEST

CAD-MDD/CAT-DI screening via MyChart

Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).

DIAGNOSTIC_TEST

CAD-MDD/CAT-DI screening during clinic visit

During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).

OTHER

CAT-DI monitoring via MyChart

Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (\<50) will indicate that a patient's MDD is in remission.

OTHER

PHQ-9 monitoring during clinic visits

During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT03832283 - Patient Outcomes Reporting for Timely Assessments of Life With Depression: PORTAL-Depression | Biotech Hunter | Biotech Hunter